STIKO-Empfehlung zur COVID-19-Impfung bei Personen mit Immundefizienz (ID)
K King, S Vygen-Bonnet, GD Burchard, U Heininger… - 2021 - edoc.rki.de
Die STIKO empfiehlt bisher ungeimpften Personen mit einer Immundefizienz zunächst 2
Impfstoffdosen eines mRNA-Impfstoffs im Abstand von 3–6 (Comirnaty) bzw. 4–6 Wochen …
Impfstoffdosen eines mRNA-Impfstoffs im Abstand von 3–6 (Comirnaty) bzw. 4–6 Wochen …
What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of …
F Aldunate, A Fajardo, N Ibañez, F Rammauro… - Frontiers in …, 2023 - frontiersin.org
Coronavirus disease 2019 (COVID-19), an infectious disease caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, can have a wide range of clinical …
respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, can have a wide range of clinical …
COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacy
Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …
available as soon as there are survivors. The COVID-19 pandemic represented the first …
Uzroci trombocitopenije u oboljelih od bolesti COVID-19
D Bežovan, Z Mitrović - Medicina Fluminensis: Medicina Fluminensis, 2022 - hrcak.srce.hr
Sažetak Trombocitopenija je česta u virusnim infekcijama, prisutna je u prosječno 18%
oboljelih od bolesti COVID-19, a obično je blaga (u rasponu od 100 do 150× 10^ 9/L) …
oboljelih od bolesti COVID-19, a obično je blaga (u rasponu od 100 do 150× 10^ 9/L) …
What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of …
A Fabian, F Alvaro, I Natalia, R Florencia, D Hellen… - 2023 - redi.anii.org.uy
Coronavirus disease 2019 (COVID-19), an infectious disease caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, can have a wide range of clinical …
respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, can have a wide range of clinical …
[HTML][HTML] ¿ What did we learn from Convalescent plasma treatment in a COVID-19 patient two-time kidney transplanted? A case report from the viral and immune …
F Aldunate, A Fajardo, F Rammauro, H Daghero… - 2022 - europepmc.org
Background: COVID-19, an infectious disease caused by SARS-CoV-2 virus, can provoke a
vast range of clinical manifestations, ranging from asymptomatic to potentially life …
vast range of clinical manifestations, ranging from asymptomatic to potentially life …
[PDF][PDF] Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of System-atic Reviews. Diagnostics 2021, 11, 1663
Convalescent plasma (CP) from patients recovered from COVID-19 is one of the most
studied anti-viral therapies against SARS-COV-2 infection. The aim of this study is to …
studied anti-viral therapies against SARS-COV-2 infection. The aim of this study is to …
[PDF][PDF] COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review. 2
Interventions–Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration 111
http://www. cochranehandbook. org.]. The Cochrane'Risk of bias' tool for RCTs addresses …
http://www. cochranehandbook. org.]. The Cochrane'Risk of bias' tool for RCTs addresses …
[PDF][PDF] EpidemiologischesBulletin
ESI beim Robert - Epidemiologisches Bulletin, 2019 - edoc.rki.de
Abstract Der demografische Wandel, neue Gesundheitsbedrohungen, gesundheitliche und
Versorgungsungleichheiten in und zwischen Staaten der Europäischen Union (EU) stellen …
Versorgungsungleichheiten in und zwischen Staaten der Europäischen Union (EU) stellen …